GENE ONLINE|News &
Opinion
Blog

2021-11-03| Asia-Pacific

Japanese Software Company Acquires Insilico to Build Bioprocess Solutions

by Kathy Huang
Share To

Electrical engineering companies branching out into the field of biotechnology has been a trend in the last decade.

On November 2, Japanese software company Yokogawa announced that it has acquired Insilico Biotechnology to foster digital transformation in pharmaceutical development. The payment of the deal is undisclosed.

 

Expertise in Data-driven Bioprocess Technology

Insilico, a German biotech company, is known for its bioprocess software. For example, in the cell culture process, Insolico’s AI solutions can collect real-time data like pH parameters and oxygen concentration which may serve as control factors for professionals to improve the cell culture environment.

Another data-based tool developed by Insilico is its digital twin technology. The hybrid models can elaborate the metabolisms of bacteria or other cellular organisms.

Also, in bioprocess manufacturing, the self-learning model enables early detection of the faults in the metabolism process. 

“I firmly believe that the innovative digital twin technology offered by Insilico, which has a proven track record with major biopharmaceutical companies, will accelerate digital transformation in the bioprocessing industry,” Hiroshi Nakao, vice president of Yokogawa said. “ We will leverage our engineering technology and develop our business with a view to the commercialization of bioprocesses.”

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!